公开(公告)号：US20160200735A1

公开(公告)日：2016-07-14

申请号：US14995556

申请日：2016-01-14

申请人： THESAN PHARMACEUTICALS, INC.

发明人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

IPC分类号： C07D495/04

CPC分类号： C07D495/04 ,  A61K9/0014 ,  A61K31/4365

摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

公开(公告)号：US09938289B2

公开(公告)日：2018-04-10

申请号：US14995556

申请日：2016-01-14

申请人： THESAN PHARMACEUTICALS, INC.

发明人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

IPC分类号： C07D495/04 ,  A61K9/14 ,  A61K31/4365 ,  A61K9/00

CPC分类号： C07D495/04 ,  A61K9/0014 ,  A61K31/4365

摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

公开(公告)号：US09260450B2

公开(公告)日：2016-02-16

申请号：US14637097

申请日：2015-03-03

申请人： THESAN PHARMACEUTICALS, INC.

发明人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

IPC分类号： C07D495/04 ,  A61K31/4365 ,  A61K9/00

CPC分类号： C07D495/04 ,  A61K9/0014 ,  A61K31/4365

摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

公开(公告)号：US09090625B2

公开(公告)日：2015-07-28

申请号：US13864457

申请日：2013-04-17

申请人： Thesan Pharmaceuticals, Inc.

发明人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

IPC分类号： A61K31/4365 ,  C07D495/04

CPC分类号： C07D495/04 ,  A61K9/0014 ,  A61K31/4365

摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

摘要翻译： 本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐， 可用作治疗TGF-bgr介导的病症，包括癌症和纤维化疾病的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

公开(公告)号：US20150175624A1

公开(公告)日：2015-06-25

申请号：US14637097

申请日：2015-03-03

申请人： THESAN PHARMACEUTICALS, INC.

发明人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

IPC分类号： C07D495/04 ,  A61K9/00

CPC分类号： C07D495/04 ,  A61K9/0014 ,  A61K31/4365

摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

摘要翻译： 本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐， 可用作治疗TGF-bgr介导的病症，包括癌症和纤维化疾病的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。